# Supplementary information



*Figure S1: Dose-dependence curves of PANC-1, Mia-Paca2, BxPC3, RLT-PSC treated with different concentrations of scDb-hERG1-β1 and Gemcitabine for 24 hours. The intercept between the black curve and the red line indicates the IC50 value.*

|  | Control | Gemcitabine 25mg/Kg | Gemcitabine 5mg/Kg | scDb-hERG1-β1 | **Mean survival time (Days)** |
|---|---|---|---|---|---|
| Control | - |  |  |  | 67 |
| Gemcitabine 25mg/Kg | 0.83 | - | - | - | 77 |
| Gemcitabine 5mg/Kg | 0.22 | **0.02** | - | - | 59 |
| scDb-hERG1-β1 | 0.10 | 0.44 | **0.05** | - | 79 |
| scDb-hERG1-β1 + Gemcitabine 5mg/Kg | 0.33 | 0.81 | 0.10 | 0.71 | 82 |

*Table S1: Pairwise comparison for Kaplan-Meier survival curve. The p values calculated with Long-Rank test are reported. The last column show mean survival time of all the treatment groups.*



*Figure S2: Abdominal gross view at the end-point (the day of euthanasia) showed abnormal liver in mice treated with Gemcitabine at the dose of 25 mg/kg, while in the other groups of treatment no abnormalities were observed.*

***Figure S3: Whole blots of figure 1C (A) and figure 1D (B) with densitometry readings/intensity ratio of each band.***